Text
The access gap
Screening is not about expecting bad news. It is about reducing uncertainty, and giving you and your clinician more options while there are more options to have.
Dr. Scott Tackett
President & CEO
Improving screening rates requires systems thinking to understand not only where services exist, but how patient screening can be made more accessible, accommodating, acceptable and equitable.
Improving one dimension without addressing the others can still leave people unable to access care.
Sources: Lung Cancer Policy Network (2023). Case study: the US national lung cancer screening programme. American Lung Association (2025). State of Lung Cancer: key findings. Bandi, P., et al. (2025). Lung cancer screening uptake in the United States, 2024. JAMA.
Originally shared on LinkedIn
Join the conversation and see how others have responded.
Advancing infrared applications for earlier detection — beginning with lung cancer.
AIR-DS is a UKCA marked in vitro diagnostic medical device, developed in accordance with IEC 62304 and under an ISO 13485 certified quality management system. In the US, a CLIA certified laboratory will offer a laboratory developed test (LDT) with AIR-DS Lung Test. It has not been cleared or approved by the FDA. Information on this website is provided for educational and informational purposes and should not be interpreted as medical advice.